AUSTIN, Texas--(BUSINESS WIRE)--Emergent Technologies, Inc. announced today that its portfolio company, Receptor Logic, has entered into an exclusive License Agreement with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma and allergic diseases, and cancer. The agreement gives Xencor the exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.
